Table 1.
Some genes affected by chronic fluoxetine treatment in different brain preparations.
| Gene | FACS, cerebral astrocytes* | Cultured astrocytes | FACS or otherwise identified cerebral neurons*+ | Brain (different regions) | Raphe |
|---|---|---|---|---|---|
| ADAR1 | Unaltered Li et al. (2012) | Unaltered Li et al. (2011a) | Unaltered Li et al. (2012) | ||
| ADAR2 | Up Li et al. (2012) | Up Li et al. (2011a) | Unaltered Li et al. (2012) | Up Li et al. (2011a) | |
| GluK1 | Absent Li et al. (2012) | Absent Li et al. (2011a) | Absent** Li et al. (2012) | ||
| GluK2 | Up Li et al. (2012) | Up Li et al. (2011a) | Unaltered Li et al. (2012) | Up Li et al. (2011a) | |
| GluK2 editing | Up Li et al. (2012) | Up Li et al. (2011a) | Unaltered Li et al. (2012) | Up Li et al. (2011a) | |
| GluK3 | Unaltered Li et al. (2012) | Unaltered Li et al. (2011a) | Unaltered Li et al. (2012) | ||
| GluK4 | Unaltered Li et al. (2012) | Unaltered Li et al. (2011a) | Up Li et al. (2012) | ||
| GluA1 | Up Barbon et al. (2011) | ||||
| GluA2 | Up in dendrites Rubio et al. (2013) | Up Ampuero et al. (2010), Vialou et al. (2010), Barbon et al. (2011) | |||
| GluA3 | Up Barbon et al. (2011) | ||||
| GluA4 | Up Barbon et al. (2011) | ||||
| mGlu5 | Unaltered Hertz et al. (2014a) | Unaltered Hertz et al. (2014a) | |||
| mGlu7 | Up Ampuero et al. (2010), O’Connor et al. (2013) | ||||
| cPLA2a | Up Li et al. (2012) | Up Li et al. (2009) | Unaltered Li et al. (2012) | Up Rao et al. (2006) | |
| sPLA2 | Unaltered Li et al. (2012) | Unaltered Li et al. (2009) | Up Li et al. (2012) | Up Peng et al. (2014) | |
| iPLA2 | Unaltered Li et al. (2012) | Unaltered Li et al. (2009) | Unaltered Li et al. (2012) | ||
| Cav1.2 | Up Du et al. (2014) | Up Du et al. (2014) | Unaltered Du et al. (2014) | ||
| Cav1.3 | Unaltered Du et al. (2014) | Unaltered Du et al. (2014) | |||
| 5-HT2A receptor | Unaltered Li et al. (2012) | Unaltered Li et al. (2012) | |||
| 5-HT2B receptor | Up Li et al. (2012) | Up Hertz et al. (2014a) | Unaltered Li et al. (2012) | ||
| 5-HT2B editing | Up Li et al. (2012) | Up Hertz et al. (2014a) | Unaltered Li et al. (2012) | ||
| 5-HT2C receptor | Unaltered Li et al. (2012) | Unaltered Hertz et al. (2014a) | Up Li et al. (2012) | ||
| 5-HT2C editing | Up Gurevich et al. (2002), Englander et al. (2005), Schmauss et al. (2010) | ||||
| 5-HT1A receptor | Unaltered Peng et al. (2014) | Unaltered Peng et al. (2014) | Unaltered Le Poul et al. (2000), Johnson et al. (2009) | Down Le Poul et al. (2000) | |
| 5-HT1B receptor | Up or Unaltered Anthony et al. (2000), Le Poul et al. (2000) | Down Anthony et al. (2000) | |||
| SERT | Absent Li et al. (2012) | Absent Kong et al. (2002) | Absent Li et al. (2012) | Unaltered Johnson et al. (2009) | Down Lesch et al. (1993) |
| EGF receptor | Unaltered Peng et al. (2014) | Unaltered Peng et al. (2014) | |||
| Nucleoside transporter ENT2 | Up Li et al. (2013) | Up Li et al. (2013) |
*The cells isolated by FACS were freshly obtained (see text) from mice treated for 2 weeks with fluoxetine hydrochloride, 10 mg/kg per day, i.p. The cultured cells were treated with fluoxetine concentrations between 1 and 10 μM. for 14 days. For brain and raphe the treatment varied between 7 and 14 days (e., 14 days for sPLA2, but 7 days for GluK2). +FACS unless otherwise indicated. **present at low density in cultured hippocampal neurons (Li et al., 2011a).